Xeris Biopharma Holdings, Inc. (XERS)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 20 | 50 | 110 | 164 | 203 | 292 | 335 | 387 |
| Operating profit | $m | 25 | 37 | ||||||
| Net profit | $m | -91 | -123 | -95 | -62 | -55 | 1 | -17 | -7 |
| EPS reported | $ | 0.00 | -0.10 | ||||||
| Operating cashflow per share | $ | 0.18 | 0.38 | ||||||
| Capex per share | $ | 0.00 | 0.01 | ||||||
| FCF per share | $ | 0.17 | 0.38 | ||||||
| Free cash flow | $m | 28 | 55 | ||||||
| Net debt | $m | -73 | 131 | ||||||
| Book value equity | $m | 14 | -10 | ||||||
| Book value per share | $ | 0.08 | -0.06 | ||||||
| Number of shares | m | 172.74 | 172.82 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 92.00 | -129.38 | ||||||
| P/S LTM | x | 4.32 | 3.75 | ||||||
| P/FCF LTM | x | 45.09 | 22.74 | ||||||
| EV/EBITDA LTM | x | 93.32 | 72.26 | ||||||
| EV/Sales LTM | x | 4.06 | 4.58 | ||||||
| Earnings Yield LTM | % | +0.04% | -1.25% | ||||||
| FCF Yield | % | +2.22% | +4.40% | ||||||
| Quality | |||||||||
| ROE | % | +4.05% | -426.33% | ||||||
| ROIC | % | +8.89% | +12.51% | ||||||
| Operating margin | % | +8.53% | +10.91% | ||||||
| Gross margin | % | +81.70% | +83.34% | ||||||
| FCF/Sales | % | +9.57% | +19.36% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +43.72% | +65.17% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 0.74 | 0.19 | ||||||
| Net Debt/EBITDA | x | -5.77 | 10.22 | ||||||
| EBIT/Net interest | x | 0.86 | 1.30 | ||||||
| Net debt/market cap | % | +3.00% | +18.48% | ||||||
| Net debt/Equity | x | -5.35 | -13.44 | ||||||
| Gross debt/equity | x | 2.76 | -29.74 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic, hypokalemic, and related forms of primary periodic paralysis. Recorlev: A cortisol synthesis inhibitor approved for managing endogenous hypercortisolemia in adult patients with Cushing's syndrome. Beyond its marketed products, the company maintains an active development pipeline. This pipeline seeks to broaden the applications and indications for existing treatments and introduce novel pharmaceuticals leveraging its proprietary XeriSol and XeriJect formulation technology platforms. Founded in 2005, Xeris Biopharma is headquartered in Chicago, Illinois.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Xeris Biopharma Holdings, Inc. (XERS)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic, hypokalemic, and related forms of primary periodic paralysis. Recorlev: A cortisol synthesis inhibitor approved for managing endogenous hypercortisolemia in adult patients with Cushing's syndrome. Beyond its marketed products, the company maintains an active development pipeline. This pipeline seeks to broaden the applications and indications for existing treatments and introduce novel pharmaceuticals leveraging its proprietary XeriSol and XeriJect formulation technology platforms. Founded in 2005, Xeris Biopharma is headquartered in Chicago, Illinois.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free